Zhaoke Ophthalmology (HKSE:06622) FCF Margin % : -2,840.77% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Zhaoke Ophthalmology FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Zhaoke Ophthalmology's Free Cash Flow for the six months ended in Dec. 2023 was HK$-231.35 Mil. Zhaoke Ophthalmology's Revenue for the six months ended in Dec. 2023 was HK$8.14 Mil. Therefore, Zhaoke Ophthalmology's FCF Margin % for the quarter that ended in Dec. 2023 was -2,840.77%.

As of today, Zhaoke Ophthalmology's current FCF Yield % is -56.31%.

The historical rank and industry rank for Zhaoke Ophthalmology's FCF Margin % or its related term are showing as below:

HKSE:06622' s FCF Margin % Range Over the Past 10 Years
Min: -2234.34 Med: -2234.34 Max: -2234.34
Current: -2234.34

During the past 5 years, the highest FCF Margin % of Zhaoke Ophthalmology was -2234.34%. The lowest was -2234.34%. And the median was -2234.34%.

HKSE:06622's FCF Margin % is ranked worse than
83.16% of 1045 companies
in the Biotechnology industry
Industry Median: -139.31 vs HKSE:06622: -2234.34

Zhaoke Ophthalmology FCF Margin % Historical Data

The historical data trend for Zhaoke Ophthalmology's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zhaoke Ophthalmology FCF Margin % Chart

Zhaoke Ophthalmology Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

-2,234.34

Zhaoke Ophthalmology Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Margin %	Get a 7-Day Free Trial				-	-	-	-1,834.89	-2,840.77

Competitive Comparison of Zhaoke Ophthalmology's FCF Margin %

For the Biotechnology subindustry, Zhaoke Ophthalmology's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zhaoke Ophthalmology's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zhaoke Ophthalmology's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Zhaoke Ophthalmology's FCF Margin % falls into.

Zhaoke Ophthalmology FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Zhaoke Ophthalmology's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-458.218	/	20.508
	=	-2,234.34 %

Zhaoke Ophthalmology's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-231.352	/	8.144
	=	-2,840.77 %

Zhaoke Ophthalmology FCF Margin % Related Terms

Thank you for viewing the detailed overview of Zhaoke Ophthalmology's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Zhaoke Ophthalmology (HKSE:06622) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zhaoke Ophthalmology Ltd (HKSE:06622) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 1 Meide 3rd Road, Pearl River Industrial Park, Nansha District, Guangdong Province, Guangzhou, CHN

Website

https://www.zkoph.com

Zhaoke Ophthalmology Ltd is an ophthalmic pharmaceutical company. It is dedicated to the research, development, and commercialization of therapies that address unmet medical needs in China. The company has built a comprehensive ophthalmic drug pipeline of 26 candidates that covers ocular indications affecting the front and the back of the eye, through either in-house development or in-licensing. It has also established an ophthalmic manufacturing facility and is assembling an experienced marketing team in anticipation of a near-term product launch.

Executives

Mak Siu Hang Viola	2201 Interest of corporation controlled by you
Apstar Investment Pte Ltd	2201 Interest of corporation controlled by you
Coyote Investment Pte Ltd	2101 Beneficial owner
Gic (ventures) Pte. Ltd.	2201 Interest of corporation controlled by you
Gic Special Investments Private Limited	2102 Investment manager
Gic Private Limited	2201 Interest of corporation controlled by you
Fidelity China Special Situations Plc	2101 Beneficial owner
Fil Limited	2201 Interest of corporation controlled by you
Pandanus Associates Inc.	2201 Interest of corporation controlled by you
Pandanus Partners L.p.	2201 Interest of corporation controlled by you
Citigroup Inc.	2502 Approved lending agent
Vms Holdings Limited	2201 Interest of corporation controlled by you
Lee's Pharmaceutical Holdings Limited	2201 Interest of corporation controlled by you
Tpg Asia Genpar Vii, L.p.	2201 Interest of corporation controlled by you
Tpg Holdings Iii-a, L.p.	2201 Interest of corporation controlled by you

Zhaoke Ophthalmology (HKSE:06622) Headlines

No Headlines